In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma ...

Pfizer stock is undervalued with strong non-COVID growth, robust Q2 2025 results, and strategic R&D pivots. See more on PFE ...

Enanta Pharmaceuticals has initiated legal action against Pfizer (PFE) over a patent infringement related to Paxlovid, ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year. Demand for the drugmaker’s Paxlovid treatment spurred by the ...

Enata Pharmaceuticals is suing Pfizer in a European Union court, alleging Pfizer's Paxlovid Covid-19 antiviral violates one of its patents. Enata said its patent, published Wednesday in the European ...

In that case, Pfizer could make as much as $5.8 billion in a year from Paxlovid. That's roughly in line with the $5.3 billion cost of the supply that the government initially purchased.

Topline Pfizer said on Monday it will spend $120 million to boost production of its Covid-19 antiviral treatment Paxlovid, as the White House continues its efforts to increase access to the first ...

Pfizer's non-COVID growth was disappointing. The company didn't raise its sales outlook for COVID-19 pill Paxlovid. Pfizer also lowered its full-year adjusted earnings outlook due to an accounting ...

Doses of the anti-viral drug Paxlovid are displayed in New York, on Monday, Aug. 1, 2022. Pfizer's COVID-19 pill may provide little benefit for younger adults, while still reducing the risk of ...

In a study designed to test Paxlovid in "standard-risk" adults, Pfizer enrolled more than 1,100 people ages 18 and up. To join the study, they had to be within five days of a positive Covid-19 ...

Enata Pharmaceuticals is suing Pfizer in a European Union court, alleging Pfizer's Paxlovid Covid-19 antiviral violates one of its patents. Enata said its patent, published Wednesday in the European ...